Background
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease with unknown etiology. The major clinical features are chronic inflammatory hyperplasia and hypertrophy of the synovium, as well as joint damage in the hands and feet [1] . With progression of RA, most patients develop bone injury, joint deformity, and even permanent disability, which brings creates economic burdens for the family and society [2, 3] . Synovial fibroblasts are among the most important cells in synovial tissues, and the increase of their invasive ability is closely related to the genesis and progression of RA. Studies [4] [5] [6] have shown that synovial fibroblasts from RA patients can produce high levels of MMPs proteins to degrade all the components in the extracellular matrix, thereby enhancing the migration and invasive ability of synovial fibroblasts, and thus accelerating the progression of RA.
MicroRNAs are a class of non-coding single-stranded RNA molecules that participate in the regulation of cellular functions by modulating the transcription of target genes. In recent years, a number of studies have shown that the abnormal expression of microRNA is associated with the genesis and progression of many diseases [7] [8] [9] [10] [11] such as cancer, cardiovascular diseases, and RA. Ormseth et al. [12] showed that the expression level of miR-26a-5p was significantly up-regulated in the plasma of RA patients. However, the expression of miR-26a-5p in synovial tissues of RA patients and its role in the development and progression of RA have not been reported yet. Therefore, in the present study we investigated the expression of miR26a-5p in synovial tissues of RA patients through qPCR and Western blot analysis, and explored the effect of its expression on the invasive ability of synovial FLS cells in RA patients.
Material and Methods

Clinical specimens
We collected RA synovial tissue specimens from 55 RA patients who received total knee replacement in our hospital from January 2016 to December 2016. There were 32 male patients and 23 female patients, ages 43-74 years old, with the average age of 59.3±8.7 years. X-ray examination showed 13 cases were Stage II, 26 cases were Stage III, and 16 cases were Stage IV. Specimens from 62 patients who underwent amputation (49 cases) or total knee replacement (13 cases of OA patients) were collected as controls. All patients in the control group had no history of RA; while there were 37 males and 25 females, ages 45-73 years old, with the average age of 60.4±7.2 years. Exclusion criteria were: other rheumatic diseases, autoimmune diseases, tumor, liver, and kidney insufficiency; pregnant or lactating, as well as mental disorders; and taking immunomodulatory drugs within the previous 6 months. All the patients enrolled in this study were informed of the study contents and signed the informed consent form. Our study was approved by the Ethics Committee of Wenzhou Central Hospital.
Experimental methods and reagents
Extraction of total RNA from synovial tissues and qPCR
Total RNA of liquid-nitrogen-preserved or fresh synovial tissues were extracted using the miRNeasy RNA isolation kit (Qiagen, USA). A Real-time Quantitative PCR Detecting System (qPCR) was used to detect the relative expressions of has-miR-26a-5p (U6 was used as control) and Smad 1 mRNAs (GAPDH was used as control) in different synovial tissues. The qPCR primers are shown in Table 1 .
Western blot detection of protein expressions
Total protein of cartilage tissues was extracted by tissue total protein extraction kit (Beyotime, China). SDS-PAGE was performed (90 V-30 min, 120 V-60 min), and the proteins were transferred to a wet PVDF membrane (400 mA-90 min), which was blocked with 5% no-fat milk at 37°C for 2 h, and incubated with primary antibodies of Smad1, TGF-b1 MMP-1, MMP-3, MMP-13, or GAPDH (1: 1000, Abcam, UK) at 4°C overnight. Then, the primary antibodies were removed, and the membrane was washed 3 times with TBST before incubating with 
Validation of miR-26a-5p target genes by luciferase reporter
The binding site of miR-26a-5p on the 3'-UTR of Smad 1 gene was analyzed by searching on NCBI, miRanda, PicTar, and other web sites. The wild-type (WT) or mutated sequence (MUT) of the binding site on 3'-UTR was cloned into pmirGLO plasmid (Addgene, USA) that was double-digested by Sac I and Sal I. The constructed recombinant plasmid was co-transfected with miR-30a-5p-mimic or miR-30a-5p-NC into FLS cells, then the cells were collected 48 h after transfection and the luciferase fluorescence intensity was detected by a Dual-Luciferase system (Promega, China).
Cell transfection
miR-26a-5p-NC, miR-26a-5p-mimic, and miR-26a-5p-inhibitor (Shanghai Bioengineering Co., Ltd., China) were transfected into the isolated FLS cells according to the instructions of the purchased Lipofectamine RNAIMAX transfection kit (Invitrogen, USA). The detailed procedures were as follows: (1) 1 day before transfection, the isolated human FLS cells were plated into 6-well plates at the concentration of 1×10 6 cells per well; (2) on the day of transfection, the Lipofectamine RNAIMAX transfection reagent was mixed evenly with opti-MEM culture medium and the synthesized miR-26a-5p-NC, miR-26a-5p-mimic, or miR-26a-5p-inhibitor, and the mixtures were incubated for 5-10 min at room temperature before they were added into the cell culture medium; (3) 72 h after the transfection, cells were digested with trypsin, rinsed once with PBS, and preserved for further experiments.
Cell invasion assay
Transwell assay was performed to detect the metastasis/invasive ability of cells. The Matrigel (Becton Dickinson Company, USA) stored at -20°C was melted overnight at 2°C to 8°C on ice. We drew 100 μl Matrigel with a pre-cooled pipette tip on the ice, added pre-cooled 300 μl serum-free medium, and mixed it fully. Then, we took the above diluted 25 μl Matrigel into the Transwell board room (Costar, USA), covering the whole polycarbonate film at 37°C for 30 min, and polymerized the Matrigel into glue. The FLS cells that were transfected for 72 h were digested with trypsin (Gibco, USA), rinsed once with PBS, and resuspended with FBS-free DMEM culture medium (Hyclone, USA) to the concentration of 0.5×10 6 cells/ml. Then, the cells were loaded into the upper chambers of a 24-well Transwell plate (Corning, USA), while the lower chambers were loaded with DMEM culture medium supplemented with 20% FBS (Hyclone, USA). The Transwell plate was incubated for 24 h at 37°C. The culture medium was removed and the cells were rinsed twice with PBS before they were fixed with methanol for 30 min. Then, the membranes were dried and dyed with crystal violet for 20 min before the cells were observed and counted under an optical microscope (Leica Microsystems, German).
Flow cytometry
Collected FLS cell after different treatment. FLS cells was washed once by pre-cooled PBS solution at 4°C, then cells were added to 70% ethanol to fix overnight at 4°C. The following experiments were performed according to Annexin V-FITC/PI double-staining with Annexin V-FITC/PI Double Apoptosis Assay Kit (Shanghai Bioengineering, China), and finally by flow cytometry-MACSQuant ® Analyzer 10 (Miltenyi Biotec, Germany).
Statistical analysis method
The quantitative data are expressed as mean ± standard deviationwhile the enumeration data are expressed in the form of percentage. Pearson correlation analysis was performed to evaluate the correlation between the expression levels of miR-26a-5p and Smad 1 mRNA in synovial tissues. The differences between groups of other data were measured by t test using SPSS 20.0 software, and P<0.05 was considered statistically significant.
Results miR-26a-5p and Smad 1 were highly expressed in RA synovial tissues
Total RNA was extracted from the synovial tissues of RA patients or patients in the control group, and the relative expressions of miR-26a-5p and Smad 1 mRNA were detected by qPCR. The results showed that the relative expressions of miR-26a-5p and Smad 1 mRNA in the synovial tissues of RA patients were 7.03±1.97 and 1.98±0.74, respectively, which were both significantly higher than those of the patients in the control group (2.63±1.03 and 0.58±0.16), respectively (P<0.05), as shown in Figure 1A , 1B.
Total proteins were extracted from the synovial tissues of RA patients or patients in the control group, and Western blot was performed to detect the expression of Smad 1 protein in either of the groups. The results showed that the relative expression of Smad 1 protein in the synovial tissues of RA patients was 2.01±0.63, which was significantly higher than that of the control group (0.7±0.19) (P<0.05), as shown in Figure 1C , 1D.
Pearson correlation analysis was used to compare the correlation between the expressions of miR-26a-5p and Smad 1 mRNA in the synovial tissues, and results showed that they were positively correlated in the synovial tissues of RA patients (r=0.8982, P<0.001), as shown in Figure 1E .
Targeted regulation of Smad 1 gene expression by miR26a-5p in FLS cells
The target genes of miR-26a-5p were predicted by bioinformatics methods, and the results showed that there was a complementary sequence of miR-26a-5p at the 3'-UTR end of Smad 1 mRNA, as shown in Figure 2A . In order to verify that miR26a-5p could regulate the expression of Smad 1 by binding to the 3'-UTR end of Smad 1, a luciferase gene reporter system was applied: transfection of miR-26a-5p-mimics significantly increased the luciferase activity of wild-type Smad 1 mRNA 3'-UTR (P<0.05), while transfection of miR-26a-5p-inhibitor significantly decreased the luciferase activity of wild-type Smad 1 mRNA 3'-UTR (P<0.05). In addition, we also transfected miR-26a-5p-NC, miR-26a-5p-mimics, or miR-26a-5p-inhibitors into synovial fibroblasts, and results showed that the expression of Smad 1 was significantly increased in the synovial fibroblasts transfected with miR-26a-5p-mimics (P<0.05), while it was significantly decreased in the synovial fibroblasts transfected with miR-26a-5p-inhibitors (P<0.05), as shown in Figure 2B -2F.
MiR-26a-5p regulated the expression of MMPs-related proteins
MMPs proteins are a series of enzymes that degrade all the components of the extracellular matrix and therefore enhance cell migration and invasion. MMP-1, MMP-3, and MMP-13 are 3 MMPs proteins that have been shown to be highly expressed in RA synovial tissues and enhance the invasive ability of synovial fibroblasts in RA patients [13, 14] . In this study, we found that the expression of MMP-1, MMP-3, and MMP-13 proteins and mRNA in synovial fibroblasts decreased significantly when the cells were transfected with miR-26a-5p-inhibitors or when the expression of Smad1 was suppressed (P<0.05), as shown in Figure 3 .
miR-26a-5p regulated the invasive ability of FLS cells through Smads/TGF-b signaling pathway
At 72 h after transfection of miR-26a-5p-inhibitor and miR26a-5p into FLS cells, there was no significant change in cell viability ( Figure 4A ), while the expressions of miR-26a-5p were significantly decreased/increased in FLS cells ( Figure 4B ). 
Discussions
RA is a chronic and aggressive autoimmune disease, and the main clinical outcome is RA. For a long time, the academic community generally believed that T cells and other immune cells and their cytokines play a key role in the genesis and progression of RA [15] [16] [17] . In recent years, however, a number of studies on synovial fibroblasts isolated from RA patients have posed a strong challenge to this concept [18] . Scholars both in China and abroad have studied synovial fibroblasts from many aspects, such as signaling pathway [19] , cell apoptosis [20] , invasion, and migration [21] , and the results showed that synovial fibroblasts play a leading role in the development of RA without dependence on any external factors [18] .
miR-26a-5p is located on the human chromosome 3p22 and encodes a single-stranded RNA with 21 nucleotides. At present, there are only a few studies on its role in RA. Studies by Ormseth et al. [12] showed that the expression of miR-26a-5p in the plasma of RA patients was significantly increased. In this study, we found that the relative expression of miR26a-5p and Smad 1 gene in the synovial tissues of RA patients were significantly higher than those in the control group (P<0.05), and that the expression of miR-26a-5p in the synovial tissues of RA patients was positively correlated with the expression of Smad 1 mRNA (r=0.8982, P<0.001). In addition, it was verified by the luciferase system that Smad 1 was the target gene of miR-26a-5p. Smad1 protein is an important member of the Smads cytoplasmic protein family, and is an important transmitter on the TGF-b/Smads signaling pathway.
Researches by Chen et al. [22] pointed out that miR-345 could inhibit the proliferation, migration, and invasion of prostate cancer cells through targeted down-regulation of Smad 1 protein. Meanwhile, the study of Yong W et al. [23] in hepatocellular carcinoma also showed that inhibiting the expression of [24] found that inhibition of miR-21 expression in the synovial fibroblasts of RA patients could inhibit the expression of MMPs proteins through the TGF-b1/Smad4/7 signaling pathway, thereby reducing the invasiveness of synovial fibroblasts. In combination with the results of this study, we hypothesized that the high expression of miR-26a-5p in synovial tissues of RA patients promotes the invasion and migration of synovial fibroblasts by targeting the up-regulation of Smad 1 protein, thus accelerating the progression of RA.
We also found that inhibition of miR-26a-5p expression and silencing of Smad 1 gene in synovial fibroblasts could both inhibit the expression of MMP-1, MMP-3, and MMP-13 genes in synovial FLS cells. MMPs proteins are a series of enzymes that degrade all the components of the extracellular matrix and therefore enhance cell migration and invasion. Among them, MMP-1, MMP-3,, and MMP-13 are 3 highly expressed proteins in RA synovial tissues, which enhance the invasive ability of synovial fibroblasts in RA patients [13, 14] . Combined with the results of our study, it can be concluded that the high expression of miR-26a-5p in RA synovial tissues may promote the expression of MMP-1, MMP-3, and MMP-13 proteins by targeting the expression of the Smad 1 gene, thus promoting the invasive ability of synovial fibroblasts.
Conclusions
Our further studies showed that inhibiting the expression of miR-26a-5p in synovial fibroblasts not only significantly reduced the expression of Smad 1 and TGF-b1 proteins, but also restrained the invasive ability of synovial fibroblasts. In conclusion, miR-26a-5p is highly expressed in the synovial tissues of RA patients, and its high expression promotes the invasive ability of synovial fibroblasts by targeting Smad 1 gene expression, thus accelerating the progression of RA. Further research is needed to elucidate the mechanism of the miR-26a-5p/Smad 1 signaling pathway, and the method for pathway identification should be based on attractor and crosstalk [25] .
